Form D · Biotechnology

Therini Bio, Inc.

Sacramento, CA · CIK 0001776935

Offering snapshot reported Sep 8, 2025 · SEC filing

Reported sold
$74.9M
Offering amount: $80.8M
Investors reported
17
Form D · investor count
Minimum accepted
Not reported
Reported outside-investor minimum
First sale
Mar 29, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 8, 2025Amendment$74,870,150No comparison17SEC filing
Apr 14, 2023Initial$26,619,532No comparison8SEC filing
May 22, 2020Amendment$9,356,749$7,000,000vs May 17, 20194SEC filing
May 17, 2019Initial$2,356,749No comparison2SEC filing

Offering details

Securities
Not reported
Exemptions
Not reported
Duration over one year
Not reported
Business combination
Not reported
Sales commissions
$0
Finders' fees
$0
Form D file number
021-478843

Source: Form D, filed Sep 8, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Aikaterini Akasoglou Director
Houman Ashrafian Director
Laurence Barker Director
Daniel D Burgess Director
Laia Crespo Martin Director
Olga Danilchanka Director
David Dolby Director
Tara Nickerson Director, Executive
Michael Quigley Director, Executive
Michael Ross Director
Tracy Saxton Director
Leslie Schulze Executive
Edward Spack Executive
Jeffrey Stavenhagen Executive
Jeffrey Stavenhagen, Ph.D. Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2108 N Street Suite 4963
Sacramento, CA, 95816